Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody drugs aim to stop Catheter-Related clots

NCT ID NCT06299111

Prevention Sponsor: Regeneron Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two experimental drugs, REGN9933 and REGN7508, to see if they can prevent venous thromboembolism (blood clots) in adults who need a PICC line for at least 14 days. The drugs are monoclonal antibodies that target a clotting factor. 195 participants received a single IV dose of one of the drugs or a placebo. Researchers measured how many people developed clots, as well as side effects and bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
REGN9933 and REGN7508 (monoclonal antibodies against factor XI)
What this could lead to
If successful, these drugs could offer a new way to prevent dangerous blood clots in people with central catheters, potentially reducing the need for standard blood thinners.
What could go wrong
This is an early Phase 2 trial with only 195 participants, so results may not apply to everyone. The drugs could cause bleeding or other side effects, and they may not work better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

195 people

The number who actually took part.

Started

Sep 2024

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: 1. PICC is clinically indicated for at least 14 days and is anticipated to remain in place for at least 14 days 2. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤2 or equivalent functional status as described in the protocol 3. Body weight ≥45 kg and ≤130 kg during the screening period 4. International normalized ratio (INR) and aPTT values at or below the upper limit of normal as defined by the local lab during the screening period 5. Platelet count ≥100 x 10\^9/L during the screening period as described in the protocol Key Exclusion Criteria: 1. Unsuccessful PICC placement or any other complication associated with this procedure that in the opinion of the study investigator may present any safety concerns to the participant 2. History of prior venous thrombosis in the arm in which the PICC is to be placed 3. Peripheral catheter(s) in the same arm in which the PICC is to be placed or expected need for peripheral catheter(s) placement in the same arm the PICC is to be placed as described in the protocol 4. History of known thromboembolic disease or thrombophilia 5. Participants requiring therapeutic anticoagulation and/or antiplatelet therapy as described in the protocol 6. Expected to receive cancer therapy or other medication associated with a prior episode of Grade 4 thrombocytopenia as described in the protocol 7. Any history of intracranial or intraocular bleeding, excessive operative or post-operative bleeding, traumatic spinal or epidural anesthesia, or history of bleeding diathesis (such as but not limited to Hemophilia A or B, von Willebrand's disease, fibrinogen deficiency, and other inherited or acquired bleeding disorders) as described in the protocol Note: Other protocol defined inclusion/exclusion criteria apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Venous thromboembolism are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

venous thromboembolism prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Venous thromboembolism

Contacts and locations

Locations

  • Arensia Exploratory Medicine Clinic at Country Hospital Cluj-Napoca

    Cluj-Napoca, 400006, Romania

  • Arensia Research Clinic

    Bucharest, 011658, Romania

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Cardiff and Vale University Health Board - University Hospital Wales

    Cardiff, Wales, CF14 4XW, United Kingdom

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048, United States

  • Hadassah University Medical Center

    Jerusalem, 91120, Israel

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Juravinski Hospital

    Hamilton, Ontario, L8V 1C3, Canada

  • Lakeridge Health

    Oshawa, Ontario, L1G 2B9, Canada

  • Lanadio Medical Center

    Netanya, 4244916, Israel

  • London Health Sciences Centre

    London, Ontario, N6A 4L6, Canada

  • Memorial Sloan Kettering

    New York, New York, 10065, United States

  • Mount Sinai Medical Center

    New York, New York, 10029, United States

  • Rabin Medical Center

    Petah Tikva, 49100, Israel

  • Shaare Zedek Medical Center

    Jerusalem, Jerusalem, 9103102, Israel

  • Sheba Medical Center

    Ramat Gan, 5265601, Israel

  • Soroka University Medical Center

    Beersheba, Southern District, 84101, Israel

  • Sveta Sofia Hospital

    Sofia, 1000, Bulgaria

  • Sylvester Comprehensive Cancer Center

    Miami, Florida, 33136, United States

  • Tel Aviv Sourasky Medical Center

    Tel Aviv, 64239, Israel

  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust

    Newcastle upon Tyne, NE1 4LP, United Kingdom

  • University Health Network

    Toronto, Ontario, M5G 2M9, Canada

  • University hospital Southampton

    Southampton, Hampshire, SO16 6YD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.